Suchergebnisse - "Yates, James W T"

PubPharm (6)

1

Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Colclough, N. | Chen, K. | Johnström, P. | +32

2

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC : The AURA Leptomeningeal Metastases Analysis

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Ahn, M. | Chiu, C. | Cheng, Y. | +12

3

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent

enthalten in: Journal of medicinal chemistry | 2018

von Foote, K. | Nissink, J. | McGuire, T. | +11

4

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2016

von Ballard, P. | Yates, J. | Yang, Z. | +14

5

Irreversible Inhibition of EGFR : Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104

enthalten in: Molecular cancer therapeutics | 2016

von Yates, J. | Ashton, S. | Cross, D. | +3

6

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

enthalten in: Molecular cancer therapeutics | 2015

von Guichard, S. | Curwen, J. | Bihani, T. | +15

1
[1]